Vivos Therapeutics Inc (VVOS)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$0.19+6.76%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · VVOS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -89.8% |
| Our one-year growth estimate | diamond | 48.4% |
Growth built into the price is above our model estimate.
The price assumes 138.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
VVOS — CFO transition
Dated 2026-08-03
Chief Financial Officer — Bradford Amman: Mr. Amman resigned as Chief Financial Officer and Secretary, with an orderly transition plan in place.
Why it matters: The company is at risk of delisting due to low stock price. Staying compliant is crucial for operations.
Worry ifA press release says they meet Nasdaq's minimum bid price of $1.00 per share.
Less concerning ifA further notice of delisting or failure to meet compliance by the deadline.
Why it matters: A strong patent position could help Vivos compete better in the OSA market.
Supportive ifManagement says there is more interest or sales linked to the new patent.
Worry ifThere is no clear impact on sales or market interest from the new patent.
Why it matters: Starting AIM Florida could increase revenue from sleep apnea treatments. It may also boost profits.
Supportive ifAIM Florida begins work with a full Sleep Optimization Team.
Worry ifAIM Florida does not launch as planned or faces significant delays.
Why it matters: Fixing compliance issues is key to keeping the Nasdaq listing. It impacts investor trust and stock stability.
Watch forThe company announces a plan that resolves the Nasdaq compliance issue by July.
Also watch forIf no resolution is announced by July, it may lead to delisting.
Why it matters: The new patent helps Vivos' intellectual property. This can improve its competitive edge and market share.
Supportive ifThe new patent leads to more sales or partnerships due to better product protection.
Worry ifThe patent does not lead to any market advantages or sales growth.
Why it matters: Controlling operating costs is important for better financial health. A drop shows good cost control.
Supportive ifOperating expenses decline from $6.6M in Q1 to below $6.0M in Q2.
Worry ifOperating costs rise or stay above $6.6M in Q2.
Why it matters: Increased referrals signal growing demand for Vivos' services, which can boost revenue. This is crucial for their new business model.
Supportive ifTotal incoming referrals more than double in the Las Vegas market since May-June 2026.
Worry ifReferrals drop or do not increase as expected. This shows possible issues with demand.
Why it matters: Managing costs is key for better financial health. It helps the company grow.
Supportive ifOperating costs are steady or lower than in previous quarters.
Worry ifOperating expenses are still rising. This makes financial losses worse.
Why it matters: A big revenue increase would show that Vivos' new business strategy works. It would also show operational improvements.
Supportive ifQ2 revenue growth exceeds 16% compared to Q2 2025.
Worry ifQ2 revenue growth is less than 16% year over year.
Why it matters: The patent helps Vivos' market position. It may lead to more sales of its devices.
Supportive ifSales of Vivos CARE devices rise by 20% after the patent is issued.
Worry ifSales remain flat or decline despite the new patent protection.
Why it matters: The rights offering could help Vivos' finances. It would support ongoing operations during losses.
Supportive ifThe SEC says the registration statement is effective. This allows the rights offering to move forward.
Worry ifThe rights offering is delayed or canceled. This would hurt efforts to raise capital.
Why it matters: The partnership plans to make over $6 million each year. This helps Vivos grow revenue.
Supportive ifRevenue from the SPCVA partnership is over $1 million in the first quarter.
Worry ifRevenue from the partnership falls short of $1 million in the first quarter.
Why it matters: Fixing compliance issues is key to keeping the company's listing and investor trust.
Supportive ifThe company gets confirmation that it meets Nasdaq listing rules.
Worry ifThe company gets more notices of non-compliance from Nasdaq.
Why it matters: New partnerships can drive growth and improve market position. This is a key management priority.
Supportive ifThere is news of more partnerships beyond the recent one with SPCVA.
Worry ifNo new partnerships were announced. This shows slow growth efforts.
Why it matters: This facility will double yearly revenue to over $10 million. It shows Vivos meets patient needs for sleep apnea services.
Supportive ifThe facility opens on August 27, 2026. It will generate more than $10 million in annual revenue.
Worry ifThe facility opens but does not reach revenue goals or has problems running.
Why it matters: This partnership aims to generate over $6 million each year. Success could prove Vivos' strategy of expanding partnerships.
Supportive ifAIM Florida reports revenue over $6 million in the first year.
Worry ifAIM Florida does not make the expected revenue or has problems running.
Why it matters: Updates on compliance may affect Vivos' listing status. This could impact their ability to attract investment.
Worry ifNasdaq confirms Vivos is back in compliance with listing rules.
Less concerning ifNasdaq sends more warnings about non-compliance. This could lead to delisting.
Why it matters: Strong revenue growth shows Vivos is changing its business model and gaining traction.
Supportive ifQ2 revenue growth is over 15% compared to last year. This shows a good strategy.
Worry ifQ2 revenue growth is below 10% year over year, suggesting challenges in the new model.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$402 on $10,000 · ±4.0% | How much price usually moves either way. |
| Bad day | $953 loss on $10,000 · 9.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,591 loss on $10,000 · 95.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.